Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885
View directory record Official record
Conditions
HIV-1-infection, Elevated Cardiovascular Risk
Interventions
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Not yet recruiting Not applicable Interventional

CGM Use in Heart Failure

NCT07045298
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus
Interventions
Libre 2 rt-CGM, POC BG + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 28, 2026, 7:46 AM EDT
Not yet recruiting Phase 3 Interventional

Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction

NCT07880743
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Dave Bernholt
Other
Eligibility
14 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Skokie, Illinois • St Louis, Missouri • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E

NCT01700426
View directory record Official record
Conditions
Iron Deficiency, Iron Deficiency Anemia
Interventions
Vitamin E, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Months to 2 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 28, 2026, 7:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis

NCT01952847
View directory record Official record
Conditions
Advanced Cancers
Interventions
Placebo, Glutamine, Questionnaires
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
17 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NCT03000348
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cysteamine, Placebo Oral Capsule
Drug
Lead sponsor
NovaBiotics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT06525935
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT02484690
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Active, not recruiting Not applicable Interventional

Insulin Detemir in Obesity Management

NCT01239550
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Detemir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
31 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753
View directory record Official record
Conditions
Primary Generalized Epilepsy
Interventions
Cenobamate, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 28, 2026, 7:46 AM EDT
Completed No phase listed Observational Results available

Follow-Up Study for Exubera

NCT00734591
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera, Randomized diabetes therapy
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
131
States / cities
Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Not listed Phase 2Phase 3 Interventional

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

NCT01094340
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Not applicable Interventional

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

NCT03971097
View directory record Official record
Conditions
Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
McKeesport, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 28, 2026, 7:46 AM EDT